TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 168 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $170,853 | -60.5% | 20,785 | +8.1% | 0.00% | -100.0% |
| Q1 2024 | $432,595 | +131.5% | 19,235 | -7.5% | 0.00% | – |
| Q4 2023 | $186,857 | +0.6% | 20,785 | 0.0% | 0.00% | – |
| Q3 2023 | $185,818 | -41.5% | 20,785 | +0.5% | 0.00% | -100.0% |
| Q2 2023 | $317,722 | -26.6% | 20,685 | +7.5% | 0.00% | 0.0% |
| Q1 2023 | $432,595 | +6.9% | 19,235 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $404,512 | -33.1% | 19,235 | -21.7% | 0.00% | -50.0% |
| Q3 2022 | $605,000 | +1.7% | 24,555 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $595,000 | -6.0% | 24,555 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $633,000 | -16.9% | 24,555 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $762,000 | +25.5% | 24,555 | -1.9% | 0.00% | 0.0% |
| Q3 2021 | $607,000 | +66.3% | 25,038 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $365,000 | -35.7% | 25,038 | +10.0% | 0.00% | 0.0% |
| Q1 2021 | $568,000 | -76.9% | 22,765 | -74.7% | 0.00% | -80.0% |
| Q4 2020 | $2,455,000 | – | 90,065 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |